Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis.

Babu S, Macklin EA, Jackson KE, Simpson E, Mahoney K, Yu H, Walker J, Simmons Z, David WS, Barkhaus PE, Simionescu L, Dimachkie MM, Pestronk A, Salameh JS, Weiss MD, Brooks BR, Schoenfeld D, Shefner J, Aggarwal S, Cudkowicz ME, Atassi N.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Oct 14:1-9. doi: 10.1080/21678421.2019.1672750. [Epub ahead of print]

PMID:
31608711
2.

Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: New and novel agents.

Farmakidis C, Dimachkie MM, Pasnoor M, Barohn RJ.

Muscle Nerve. 2019 Sep 18. doi: 10.1002/mus.26711. [Epub ahead of print] Review.

PMID:
31531874
3.

Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part I: Traditional agents.

Farmakidis C, Dimachkie MM, Pasnoor M, Barohn RJ.

Muscle Nerve. 2019 Sep 11. doi: 10.1002/mus.26708. [Epub ahead of print] Review.

PMID:
31509257
4.

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA; RESILIENT Study Group.

Lancet Neurol. 2019 Sep;18(9):834-844. doi: 10.1016/S1474-4422(19)30200-5.

PMID:
31397289
5.

Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis.

Ramdharry G, Morrow J, Hudgens S, Skorupinska I, Gwathmey K, Currence M, Herbelin L, Jawdat O, Pasnoor M, Mcvey A, Barohn RJ, Burns TM, Dimachkie MM, Amato AA, Hanna MG, Machado PM.

Muscle Nerve. 2019 Aug;60(2):161-168. doi: 10.1002/mus.26521. Epub 2019 Jun 7. Erratum in: Muscle Nerve. 2019 Oct;60(4):484.

PMID:
31107564
6.

Subcutaneous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Nursing Perspective.

Watkins JM, Dimachkie MM, Riley P, Murphy E.

J Neurosci Nurs. 2019 Aug;51(4):198-203. doi: 10.1097/JNN.0000000000000451.

PMID:
31107344
7.

Peripheral Neuropathy Research Registry: A prospective cohort.

Thomas S, Ajroud-Driss S, Dimachkie MM, Gibbons C, Freeman R, Simpson DM, Singleton JR, Smith AG; PNRR Study Group, Höke A.

J Peripher Nerv Syst. 2019 Mar;24(1):39-47. doi: 10.1111/jns.12301. Epub 2019 Jan 29.

PMID:
30629307
8.

Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.

Clifford KM, Hobson-Webb LD, Benatar M, Burns TM, Barnett C, Silvestri NJ, Howard JF Jr, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, Laboy SM, Fellman MA, Howard DB, Kolb NA, Greene SM, Pasnoor M, Dimachkie MM, Barohn RJ, Hehir MK.

Muscle Nerve. 2019 Apr;59(4):404-410. doi: 10.1002/mus.26404. Epub 2019 Jan 14.

PMID:
30575980
9.

Review process for IVIg treatment: Lessons learned from INSIGHTS neuropathy study.

Levine TD, Katz JS, Barohn R, Vaughan LJ, Dimachkie MM, Saperstein DS, Mozaffar T, Wolfe GI, Mayo MS, Badger GJ, Katzin L, Ritt E, Greer M, DiStefano J, Schmidt PM.

Neurol Clin Pract. 2018 Oct;8(5):429-436. doi: 10.1212/CPJ.0000000000000520. Review.

10.

Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.

Abuzinadah AR, Jabari D, Jawdat O, Pasnoor M, Glenn M, Herbelin L, McVey AL, Barohn RJ, Dimachkie MM.

J Clin Neuromuscul Dis. 2018 Dec;20(2):49-59. doi: 10.1097/CND.0000000000000219.

PMID:
30439750
11.

Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium.

Muscle Nerve. 2019 Feb;59(2):201-207. doi: 10.1002/mus.26335. Epub 2018 Nov 26.

PMID:
30192007
12.

Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Naddaf E, Barohn RJ, Dimachkie MM.

Neurotherapeutics. 2018 Oct;15(4):995-1005. doi: 10.1007/s13311-018-0658-8. Review.

13.

Toxic myopathies.

Pasnoor M, Barohn RJ, Dimachkie MM.

Curr Opin Neurol. 2018 Oct;31(5):575-582. doi: 10.1097/WCO.0000000000000606. Review.

PMID:
30080718
14.

Congenital Myasthenic Syndromes: a Clinical and Treatment Approach.

Farmakidis C, Pasnoor M, Barohn RJ, Dimachkie MM.

Curr Treat Options Neurol. 2018 Jul 21;20(9):36. doi: 10.1007/s11940-018-0520-7. Review.

PMID:
30032336
15.

Update on Inclusion Body Myositis.

Jabari D, Vedanarayanan VV, Barohn RJ, Dimachkie MM.

Curr Rheumatol Rep. 2018 Jun 28;20(8):52. doi: 10.1007/s11926-018-0755-z. Review.

PMID:
29955981
16.

Fifty Key Publications on Myasthenia Gravis and Related Disorders.

Dimachkie MM, Barohn RJ.

Neurol Clin. 2018 May;36(2):xiii-xvii. doi: 10.1016/j.ncl.2018.03.001. No abstract available.

PMID:
29655457
17.

Lambert-Eaton Myasthenic Syndrome.

Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ.

Neurol Clin. 2018 May;36(2):379-394. doi: 10.1016/j.ncl.2018.01.008. Review.

18.

Measuring Clinical Treatment Response in Myasthenia Gravis.

Barnett C, Herbelin L, Dimachkie MM, Barohn RJ.

Neurol Clin. 2018 May;36(2):339-353. doi: 10.1016/j.ncl.2018.01.006. Review.

19.

Treatment of Myasthenia Gravis.

Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ.

Neurol Clin. 2018 May;36(2):311-337. doi: 10.1016/j.ncl.2018.01.011. Review.

20.

Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Rivner MH, Pasnoor M, Dimachkie MM, Barohn RJ, Mei L.

Neurol Clin. 2018 May;36(2):293-310. doi: 10.1016/j.ncl.2018.01.004. Review.

21.

Diagnosis of Myasthenia Gravis.

Pasnoor M, Dimachkie MM, Farmakidis C, Barohn RJ.

Neurol Clin. 2018 May;36(2):261-274. doi: 10.1016/j.ncl.2018.01.010. Review.

PMID:
29655449
22.

EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report.

Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) .

RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017.

23.

2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland).

Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27. Erratum in: Arthritis Rheumatol. 2018 Sep;70(9):1532.

24.

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland).

Ann Rheum Dis. 2017 Dec;76(12):1955-1964. doi: 10.1136/annrheumdis-2017-211468. Epub 2017 Oct 27. Erratum in: Ann Rheum Dis. 2018 Sep;77(9):e64.

25.

Less is More in Diabetic Neuropathy Diagnosis: Comparison of Quantitative Sudomotor Axon Reflex and Skin Biopsy.

Abuzinadah AR, Kluding P, Wright D, DʼSilva L, Ryals J, Hendry B, Jawdat O, Herbelin L, McVey AL, Barohn RJ, Dimachkie MM, Pasnoor M.

J Clin Neuromuscul Dis. 2017 Sep;19(1):5-11. doi: 10.1097/CND.0000000000000150.

PMID:
28827483
26.

Outcome measures in the idiopathic inflammatory myopathies: On the search for the holy grail.

Dimachkie MM, Paganoni S.

Neurology. 2017 Jul 4;89(1):20-21. doi: 10.1212/WNL.0000000000004070. Epub 2017 May 31. No abstract available.

PMID:
28566551
27.

Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.

Kishnani P, Tarnopolsky M, Roberts M, Sivakumar K, Dasouki M, Dimachkie MM, Finanger E, Goker-Alpan O, Guter KA, Mozaffar T, Pervaiz MA, Laforet P, Levine T, Adera M, Lazauskas R, Sitaraman S, Khanna R, Benjamin E, Feng J, Flanagan JJ, Barth J, Barlow C, Lockhart DJ, Valenzano KJ, Boudes P, Johnson FK, Byrne B.

Mol Ther. 2017 May 3;25(5):1199-1208. doi: 10.1016/j.ymthe.2017.02.017. Epub 2017 Mar 22.

28.

Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Vander Heiden JA, Stathopoulos P, Zhou JQ, Chen L, Gilbert TJ, Bolen CR, Barohn RJ, Dimachkie MM, Ciafaloni E, Broering TJ, Vigneault F, Nowak RJ, Kleinstein SH, O'Connor KC.

J Immunol. 2017 Feb 15;198(4):1460-1473. doi: 10.4049/jimmunol.1601415. Epub 2017 Jan 13.

29.

Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.

Dimachkie MM, Abuzinadah AR, Barohn RJ, Oskarsson B, Rocke DM, Dengel K, Richman DP.

Neurology. 2016 Nov 8;87(19):2067-2068. No abstract available.

PMID:
27821567
30.

Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis.

Gang Q, Bettencourt C, Machado PM, Brady S, Holton JL, Pittman AM, Hughes D, Healy E, Parton M, Hilton-Jones D, Shieh PB, Needham M, Liang C, Zanoteli E, de Camargo LV, De Paepe B, De Bleecker J, Shaibani A, Ripolone M, Violano R, Moggio M, Barohn RJ, Dimachkie MM, Mora M, Mantegazza R, Zanotti S, Singleton AB, Hanna MG, Houlden H; Muscle Study Group and The International IBM Genetics Consortium.

Neurobiol Aging. 2016 Nov;47:218.e1-218.e9. doi: 10.1016/j.neurobiolaging.2016.07.024. Epub 2016 Aug 8.

31.

A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.

Brown AR, Gajewski BJ, Aaronson LS, Mudaranthakam DP, Hunt SL, Berry SM, Quintana M, Pasnoor M, Dimachkie MM, Jawdat O, Herbelin L, Barohn RJ.

Trials. 2016 Aug 31;17(1):428. doi: 10.1186/s13063-016-1544-5.

32.

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis.

Lee JY, Stathopoulos P, Gupta S, Bannock JM, Barohn RJ, Cotzomi E, Dimachkie MM, Jacobson L, Lee CS, Morbach H, Querol L, Shan JL, Vander Heiden JA, Waters P, Vincent A, Nowak RJ, O'Connor KC.

Ann Clin Transl Neurol. 2016 Apr 27;3(6):443-54. doi: 10.1002/acn3.311. eCollection 2016 Jun.

33.

Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.

van der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S, Pestronk A, Barohn RJ, Dimachkie MM, Goker-Alpan O, Mozaffar T, Pena LD, Simmons Z, Straub V, Guglieri M, Young P, Boentert M, Baudin PY, Wens S, Shafi R, Bjartmar C, Thurberg BL.

Mol Genet Metab. 2016 Sep;119(1-2):115-23. doi: 10.1016/j.ymgme.2016.05.013. Epub 2016 May 19.

34.

Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial.

Kluding PM, Singleton JR, Pasnoor M, Dimachkie MM, Barohn RJ, Smith AG, Marcus RL.

Phys Ther. 2017 Jan 1;97(1):20-31. doi: 10.2522/ptj.20160200.

35.

A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF Jr, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ; Methotrexate in MG Investigators of the Muscle Study Group.

Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15.

36.

Targeting protein homeostasis in sporadic inclusion body myositis.

Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, Noel J, Wang Y, McVey AL, Pasnoor M, Gallagher P, Statland J, Lu CH, Kalmar B, Brady S, Sethi H, Samandouras G, Parton M, Holton JL, Weston A, Collinson L, Taylor JP, Schiavo G, Hanna MG, Barohn RJ, Dimachkie MM, Greensmith L.

Sci Transl Med. 2016 Mar 23;8(331):331ra41. doi: 10.1126/scitranslmed.aad4583.

37.

Motor Neuron Disease.

Dimachkie MM, Barohn RJ.

Neurol Clin. 2015 Nov;33(4):xiii-xiv. doi: 10.1016/j.ncl.2015.09.001. No abstract available.

PMID:
26515631
38.

The Dilemma of the Clinical Trialist in Amyotrophic Lateral Sclerosis: The Hurdles to Finding a Cure.

Katz JS, Barohn RJ, Dimachkie MM, Mitsumoto H.

Neurol Clin. 2015 Nov;33(4):937-47. doi: 10.1016/j.ncl.2015.07.014. Review.

PMID:
26515630
39.

Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.

Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ.

Neurol Clin. 2015 Nov;33(4):889-908. doi: 10.1016/j.ncl.2015.07.010. Review.

40.

Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis).

Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM.

Neurol Clin. 2015 Nov;33(4):775-85. doi: 10.1016/j.ncl.2015.07.003. Epub 2015 Sep 8. Review.

41.

Primary Lateral Sclerosis.

Statland JM, Barohn RJ, Dimachkie MM, Floeter MK, Mitsumoto H.

Neurol Clin. 2015 Nov;33(4):749-60. doi: 10.1016/j.ncl.2015.07.007. Epub 2015 Sep 8. Review.

42.

Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis.

Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM.

Neurol Clin. 2015 Nov;33(4):735-48. doi: 10.1016/j.ncl.2015.07.006. Epub 2015 Sep 8. Review.

43.

Amyotrophic Lateral Sclerosis: A Historical Perspective.

Katz JS, Dimachkie MM, Barohn RJ.

Neurol Clin. 2015 Nov;33(4):727-34. doi: 10.1016/j.ncl.2015.07.013. Review.

PMID:
26515617
44.

Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients.

Johnson NE, Arnold WD, Hebert D, Gwathmey K, Dimachkie MM, Barohn RJ, McVey AL, Pasnoor M, Amato AA, McDermott MP, Kissel J, Heatwole CR.

Neuromuscul Disord. 2015 Aug;25(8):625-31. doi: 10.1016/j.nmd.2015.04.013. Epub 2015 May 7.

45.

Long-term neurological outcomes in West Nile virus-infected patients: an observational study.

Weatherhead JE, Miller VE, Garcia MN, Hasbun R, Salazar L, Dimachkie MM, Murray KO.

Am J Trop Med Hyg. 2015 May;92(5):1006-1012. doi: 10.4269/ajtmh.14-0616. Epub 2015 Mar 23.

46.

A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis.

Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI; Tirasemtiv in Myasthenia Gravis Study Group.

Neurotherapeutics. 2015 Apr;12(2):455-60. doi: 10.1007/s13311-015-0345-y.

47.

The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis.

Gang Q, Bettencourt C, Machado PM, Fox Z, Brady S, Healy E, Parton M, Holton JL, Hilton-Jones D, Shieh PB, Zanoteli E, De Paepe B, De Bleecker J, Shaibani A, Ripolone M, Violano R, Moggio M, Barohn RJ, Dimachkie MM, Mora M, Mantegazza R, Zanotti S, Hanna MG, Houlden H; Muscle Study Group and the International IBM Genetics Consortium(#).

Neurobiol Aging. 2015 Apr;36(4):1766.e1-1766.e3. doi: 10.1016/j.neurobiolaging.2014.12.039. Epub 2015 Jan 14.

48.

A genome-wide association study of myasthenia gravis.

Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chiò A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF Jr, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ.

JAMA Neurol. 2015 Apr;72(4):396-404. doi: 10.1001/jamaneurol.2014.4103.

49.

Acquired immune demyelinating neuropathies.

Dimachkie MM, Saperstein DS.

Continuum (Minneap Minn). 2014 Oct;20(5 Peripheral Nervous System Disorders):1241-60. doi: 10.1212/01.CON.0000455883.91426.12. Review.

PMID:
25299280
50.

Safety of aerobic exercise in people with diabetic peripheral neuropathy: single-group clinical trial.

Kluding PM, Pasnoor M, Singh R, D'Silva LJ, Yoo M, Billinger SA, LeMaster JW, Dimachkie MM, Herbelin L, Wright DE.

Phys Ther. 2015 Feb;95(2):223-34. doi: 10.2522/ptj.20140108. Epub 2014 Oct 2.

Supplemental Content

Loading ...
Support Center